Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › S100A9 levels for predicting lenalidomide and erythropoietin responsiveness

S100A9 levels for predicting lenalidomide and erythropoietin responsiveness

US Patent 10697970 · Granted Jun 30, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Small molecule pyrin-domain targeted NLRP3 inflammasome inhibitors2025
Stapled H2 pyrin peptides2024
TLR9 ligand trap2024
Soluble CD33 for treating myelodysplastic syndromes (MDS)2023
Pathways for treating patients2022
TLR9-binding chimeric antigen receptors2022
PD1 and PDL-1 expression during progression from myelodysplastic syndrome to acu2022
Inflammasome activation in myelodysplastic syndromes2022
TLR9 targeted therapeutics2021
Inflammasome activation in myelodysplastic syndromes2020
Targeted sensitization of non-del(5q) malignant cells2020
RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS2020